MARKET

BDRX

BDRX

Biodexa Pharmaceuticals plc
NASDAQ
1.290
+0.565
+77.99%
Opening 11:37 04/26 EDT
OPEN
1.660
PREV CLOSE
0.7248
HIGH
1.740
LOW
1.210
VOLUME
55.80M
TURNOVER
0
52 WEEK HIGH
21.62
52 WEEK LOW
0.6700
MARKET CAP
5.66M
P/E (TTM)
-0.1130
1D
5D
1M
3M
1Y
5Y
Biodexa Pharmaceuticals Seals Deal with Emtora Biosciences
TipRanks · 1h ago
Biodexa shares rally 126% on rapamycin licensing deal
Shares of Biodexa Pharmaceuticals soar 126% on rapamycin licensing deal. The company has entered into an exclusive worldwide license to develop and commercialize eRapa, also known as rapamyin. The rights come with $17M for a pivotal study of the drug in the treatment of an orphan disease.
Seeking Alpha · 1h ago
US Stocks Higher Following PCE Inflation Data; Nasdaq Jumps Over 200 Points
Federal Reserve's preferred measure of inflation rose more than expected in March. The Dow traded up 0.20% and the Nasdaq Composite rose 1.36% on Friday. Energy shares dipped by 1.2% as the S&P 500 fell 0.73%. Asian markets closed mostly higher on Friday; European shares were also higher.
Benzinga · 1h ago
Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Biodexa Pharmaceuticals PLC Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP. An estimated 100,000 in U.S. And Europe are afflicted with FAP, precancerous polyps.
Benzinga · 3h ago
Weekly Report: what happened at BDRX last week (0415-0419)?
Weekly Report · 4d ago
Navigating Uncertainty: Biodexa Pharmaceuticals and the Impact of Geopolitical Turmoil on Pharma’s Bottom Line
TipRanks · 6d ago
Biodexa Pharmaceuticals reports Preliminary FY results
Seeking Alpha · 6d ago
Biodexa Pharmaceuticals Reports 2023 Milestones
TipRanks · 04/19 13:27
More
About BDRX
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Webull offers Biodexa Pharmaceuticals PLC-ADR stock information, including NASDAQ: BDRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDRX stock methods without spending real money on the virtual paper trading platform.